Poniard Pharmaceuticals Inc. (PARDD) Thursday reported the termination of its agreement to merge with privately-held Allozyne Inc. on the grounds that the company formed from the merger would not qualify for listing on the Nasdaq Capital Market, thus failing to meet one of the conditions spelled out in the merger agreement. The original agreement was announced June 22, 2011.
The agreement between the two companies anticipated the creation of a combined company named Allozyne Inc. Further, the proposed listing would have required Poniard Pharma to conduct a reverse stock split in order to obtain Nasdaq compliance.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.